The development of a highly effective malaria vaccine remains a key goal to aid in the
control and eventual eradication of this devastating parasitic disease. The field has made
huge strides in recent years, with the first-generation vaccine RTS, S showing modest
efficacy in a Phase III clinical trial. The updated 2030 Malaria Vaccine Technology Roadmap
calls for a second generation vaccine to achieve 75% efficacy over two years for both
Plasmodium falciparum and Plasmodium vivax, and for a vaccine that can prevent malaria …